Stromal Vascular Fraction with Platelet-Rich Fibrin for Osteoarthritis Management in Knee and Hip Osteoarthritis: A Retrospective 2-Year Follow-Up Study

Author(s): Torbjörn Ogéus DC, PgD, MSc

Introduction: In recent years, regenerative medicine has emerged as a promising frontier in the management of various musculoskeletal disorders, including OA. Among the plethora of regenerative therapies, stromal vascular fraction (SVF) therapy combined with platelet-rich fibrin (PRF) has garnered significant attention for its potential to mitigate OA progression and promote joint regeneration.

Methods: This is a retrospective database cohort study. The clinic database was searched for patients that had undergone SVF and PRF for hip- or knee OA between January 2020 and January 2022. 104 patients were included in the study. The analyzed data were 2-year follow-up WOMAC scores and radiographic pictures before and 6 months after the treatment.

Results: Statistically significant positive changes on WOMAC scores (p = 0,0001) were presented for both hip- and knee OA. Radiographic increase of joint space in the treated joints were presented; a mean increase of 2 mm for knees and 1,6 mm for hip joints (p = 0,0001).

Conclusion: SVF combined with PRF is an effective treatment for hipand knee osteoarthritis. Significantly lowered WOMAC scores 2 years after the treatment, combined with a significant radiographic increase in joint space were presented.